New data from US centers suggest some overtesting in patients without chest pain, and undertesting in those who do.

These latest data reinforce years of smaller studies, but whether they should change practice is a matter of debate.

The ability to diagnose MI was better with troponin I, but T better predicted mortality. Both tests have strengths, ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

Underrepresentation of women as participants and researchers in CV clinical trials remains a problem, asserts a review ...

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

While intensity didn’t appear to matter in this network meta-analysis, location did: in-person programs had the most impact.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.